MedTrace Logo

A Low-osmolaric Glucose Polymer Drink for Gastric Distress and Running Performance

NCT02401152 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-12-15

No results posted yet for this study

Summary

The objective of this study is to investigate whether two newly developed sports drink will affect gastric distress (GD) and running performance (RP) compared to an iso-caloric control drink both in a short and longer distance run. Furthermore, the effect of the newly developed sports drinks on gastric emptying will be investigated.

The study will consist of 3 parts. Firstly, a randomized cross-over design is used for the short distance run and the effects on GD and RP. Secondly, a parallel design is used to study the effects of the drinks on GD and RP during a longer distance run. Thirdly, the gastric emptying tests will be performed in a randomized cross-over design. Participants will be asked to fill in questionnaire on the gastric distress they experience. 40 participants will be enrolled to participate in part 1 and part 2. 10 out of 40 will participate in part 3 of the study.

Conditions

  • Gastric Distress
  • Running Performance

Interventions

OTHER

Sports drink 1

Sports drink with a specific source of CHO.

OTHER

Sports drink 2

Sports drink with a specific source of CHO

OTHER

Placebo

iso-caloric sports drink with maltodextrin as CHO source

Sponsors & Collaborators

  • Avebe U.A.

    collaborator UNKNOWN

  • InnoSportNL

    lead OTHER

Principal Investigators

  • Jeroen Wouters, Dr. Ir.

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02401152 on ClinicalTrials.gov